Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L.
Zhang Y, et al. Among authors: wang e.
Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e150-e163. doi: 10.1016/j.clml.2022.12.008. Epub 2022 Dec 18.
Clin Lymphoma Myeloma Leuk. 2023.
PMID: 36624015